Abstract P3-06-50: Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)

Autor: J Jm van der Hoeven, Judith R. Kroep, L Gm Janssen, Hanno Pijl, G.J. Liefers, J Wr Nortier, E. Meershoek-Klein Kranenbarg, V Thbm Smit, A.E. van Leeuwen-Stok, A. van Bochove, Eveline M. Dijkgraaf, S de Groot, H Wm van Laarhoven, C Jh van de Velde, A. Charehbili, LW Kessels

Publikováno v: Cancer Research. 75:P3-06

Background: Thyroid hormones, regulators of metabolism and development in healthy tissue, stimulate tumor growth in vitro and are associated with breast cancer risk. We investigated the effect of chemotherapy on thyroid function and the extent to whi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27c2f965a7d9eee6990cbebdbd0c764d
https://doi.org/10.1158/1538-7445.sabcs14-p3-06-50

Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates.

Autor: Nguyen, Linh¹ (AUTHOR), Nguyen, Tiep Tien¹ (AUTHOR) tientiephup@skku.edu, Kim, Ju-Yeon¹ (AUTHOR) jykimac@skku.edu, Jeong, Jee-Heon¹ (AUTHOR) jeeheon@skku.edu

Publikováno v: Journal of Nanobiotechnology. 11/30/2024, Vol. 22 Issue 1, p1-19. 19p.

Pre-Incubation of Cell-Free HIV-1 Group M Isolates with Non-Nucleoside Reverse Transcriptase Inhibitors Blocks Subsequent Viral Replication in Co-Cultures of Dendritic Cells and T Cells

Autor: Harr F Njai, Paul J Lewi, Cornelus GM Janssen, Sergio Garcia, Katrien Fransen, Luc Kestens, Guido Vanham, Paul AJ Janssen

Publikováno v: Antiviral Therapy. 10:255-262

In order to study the inhibitory effect of various reverse transcriptase inhibitors (RTIs) on cell-free HIV, we adapted a recently described in vitro system, based on co-cultures of dendritic cells and resting CD4 T cells, modelling early target cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37b3373d15048464168bb24f2f3df65b
https://doi.org/10.1177/135965350501000209

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Autor: Jones DEJ; Faculty of Medical Sciences, Newcastle University, Newcastle, UK., Beuers U; Department of Gastroenterology and Hepatology, Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, The Netherlands., Bonder A; Division of Gastroenterology, Beth Israel Deaconess Medical Centre, Boston, Massachusetts, USA., Carbone M; Liver Unit, ASST Grande Ospedale, Metropolitano Niguarda, Milan, Italy., Culver E; John Radcliffe Hospital, Oxford, UK.; University of Oxford, Oxford, UK., Dyson J; Liver Unit, Freeman Hospital, Newcastle upon Tyne, UK., Gish RG; Hepatitis B Foundation, San Diego, California, USA.; Division of Gastroenterology and Hepatology, Stanford Medicine, Stanford, California, USA., Hansen BE; Department of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, The Netherlands.; University of Toronto, Toronto, Ontario, Canada.; Toronto Center for Liver Disease & Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada., Hirschfield G; Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, Ontario, Canada., Jones R; Leeds Liver Unit, St James's University Hospital, Leeds, UK., Kowdley K; Liver Institute Northwest, Elson S. Floyd College of Medicine, Washington State University, Pullman, Washington, USA.; Velocity Clinical Research, Seattle, Washington, USA., Kremer AE; Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland., Lindor K; College of Health Solutions, Arizona State University, Tempe, Arizona, USA., Mayo M; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Mells G; The Cambridge Liver Unit, Addenbrooke's Hospital, Cambridge, UK., Neuberger J; Liver and Hepato-Pancreato-Biliary Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Prince M; Department of Gastroenterology (Manchester Royal Infirmary), Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK., Swain M; University of Calgary, Calgary, Alberta, Canada., Tanaka A; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan., Thorburn D; Liver Unit, Royal Free Hospital, London, UK., Trauner M; Department of Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria., Trivedi P; National Institute for Health and Care Research, Birmingham Biomedical Research Centre, Birmingham, UK.; Liver Unit, University Hospitals Birmingham, Birmingham, UK., Weltman M; Gastroenterology and Hepatology, Nepean Hospital, Kingswood, New South Wales, Australia., Yeoman A; Aneurin Bevan University Health Board, Gwent Liver Unit, Newport, Wales, UK., Levy C; Division of Digestive Health and Liver Diseases and Schiff Center for Liver Diseases, Miami, Florida, USA.

Publikováno v: Hepatology (Baltimore, Md.) [Hepatology] 2024 Nov 01; Vol. 80 (5), pp. 1291-1300. Date of Electronic Publication: 2024 Mar 22.

Factors associated with progression and outcomes of primary biliary cholangitis: A cohort study, 2010-2019.

Autor: Javad Sajadi, Sayed Mohammad¹, Tamizifar, Babak² babaktamizifar@gmail.com, Sanei, Mohammad Hossein³, Babak, Anahita⁴

Publikováno v: Journal of Research in Medical Sciences. Sep2024, Vol. 29, p1-7. 7p.